lactamases (ESBL) 5 . ESBL-producing E. coli (ESBL-PEc) are often co-resistant to other 48
classes of antibiotics 6 . Infections caused by antibiotic-resistant E. coli strains occur with 49 increasing frequency, which potentially increase the total overall E. coli disease burden 3, 7, 8 . 50
Furthermore, in a recent modelling study, ESBL-PEc was found to be responsible for 51 approximately a third of the estimated 33.000 antibiotic-resistance related deaths in Europe in 52 2015 9 . The increasing availability of whole genome sequencing (WGS) has allowed a more 53 detailed insight into the genetics of E. coli virulence and resistance and provided further insight 54 into the distribution of acquired virulence and resistance genes in pathogenic and commensal E. 55 coli strains of different genetic backgrounds [10] [11] [12] . 56
Intestinal carriage is believed to be the most important human reservoir for ESBL-PEc from 57 which infections can originate 13 . The estimated prevalence of ESBL-PEc faecal carriage in 58 Dutch community-dwelling inhabitants ranges from 5.2% in the general population 14 to 10.1% in 59 urbanized areas 15 , and from 5.0% 16 to 6.1% 17 in hospitalized patients. Surveillance of the 60 molecular epidemiology of antibiotic resistance in the community reservoir is important to 61 identify trends in resistance development. Yet, such surveillance is labour-intensive and costly, 62 and, therefore, not regularly performed. It is currently unknown to what extent the molecular 63 epidemiology of these ESBL-PEc strains present in the Dutch community relates to the 64 molecular epidemiology of ESBL-PEc strains causing community-acquired and nosocomial E. 65 coli infections. In case of good correlations, urine E. coli isolates from primary care patients or 66 from hospitalized patients could be used for surveillance of the molecular epidemiology of 67 antibiotic-resistant E. coli in the community in the Netherlands. 68
Information on to what extent E. coli strains from different niches and patient populations in the 69
Netherlands differ genomically, is scarce. Possibly, there is also a difference in pathogenic 70 potential within invasive E. coli isolates, reflected for example by molecular differences at the 71 genome level in strains that have caused community-acquired BSI as compared to strains that 72 cause BSI in a population that is already vulnerable to infection. Such information is critical for 73 informing strategies around surveillance, prevention and treatment of this important pathogen. 74
In particular for E. coli BSI, which is characterized by high morbidity and mortality, more insight 75 in the clinical as well as molecular epidemiology in the Netherlands is needed to help identify 76 targets and potential impact of future preventive strategies such as E. coli vaccines, of which 77 one is currently being developed 18 . 78
Here, the rationale and study design of the EPIGENEC Study (EPIdemiology and GENetics of 79 E. coli) is described, which aims to 1) Investigate the association between the molecular 80 epidemiology of faecal ESBL-PEc isolates obtained from carriage in the community and from 81 clinical cultures (UTI and BSI) in the Netherlands, and 2) Characterize E. coli causing BSI in the 82 
Study design and population

92
This observational study consists of a prospective as well as a retrospective part. Four sources 93 of data and samples will be obtained from clinical care and the community (see Figure 1) . 94
Community-acquired UTI 95
Patients with a community-acquired UTI caused by ESBL-PEc were identified prospectively by a 96 positive urine culture result at Saltro, a medical laboratory providing service to primary care 97 practices, primarily in the Utrecht (city) region. Urine samples were either inoculated in 98 enrichment broth (Isobouillon with tobramycin, vancomycin and nystatin) if specifically 99 requested on ESBL or identified by elevated MIC for cephalosporins. Screening for ESBL-100 November 2017 were stored at Saltro, at -80°C. 110
Nosocomial UTI 111
Patients with nosocomial UTI caused by ESBL-PEc were retrospectively identified from medical 112 microbiological records in two participating hospitals: 1) University Medical Center Utrecht 113 (UMCU), and 2) Amphia Hospital in Breda. The UMCU is a 1,042-bed tertiary hospital, providing 114 care to the Utrecht (province) region and serves as a regional referral center. The Amphia 115
Hospital is an 837-bed teaching hospital that provides service to a region of approximately 116 ~400,000 residents. Sample inoculation and confirmation of phenotypic ESBL production was 117 performed as described for the community UTI samples, except that CHROMagar ESBL plates 118 were used (CHROMagar, Paris, France). In both hospitals, every first ESBL-PEc isolate per 119 patient is routinely stored and frozen at -80°C by the medical microbiology department. For this 120 study, we selected all ESBL-PEc isolates from nosocomial UTIs (sample taken >2 days after 121 hospital admission) during the years 2014, 2015 and 2016. 122
BSI 123
In the same two hospitals, patients with E. coli BSI, both ESBL-producing and non-ESBL-124 producing, were retrospectively identified from medical microbiological records by growth of E. 125 coli in blood cultures. In these hospitals, E. coli isolates from blood cultures are routinely stored 126 at -80°C. For the years 2014, 2015 and 2016, a random sample of 40 isolates per year, 127 comprising ~25% of all bacteraemic E. coli isolates in a year, was drawn from each hospital. In 128 addition to the random sample, all ESBL-PEc isolates from 2014-2016 were selected for WGS. 129
Consequently, this set of ESBL-PEc, together with the random sample of the bacteraemic E. 130 coli strains, comprises the total blood isolate collection for the current study (see Figure 1) . 131
All ESBL-PEc isolates obtained from the clinical samples (community UTI, nosocomial UTI and 132 BSI) and the random sample of E. coli BSI isolates were included for further molecular analyses 133 at The Netherlands National Institute for Public Health and the Environment (RIVM). Because 134 we expected follow-up cultures to often grow the same E. coli isolate as the first culture, and for 135 efficiency reasons, we selected only the first available E. coli isolate for each patient (all ages), 136 irrespective of time between cultures. 137
Community-based intestinal carriage 138
The fourth dataset consists of ESBL-PEc isolates collected from faecal samples of a national 139 population study for ESBL-producing Enterobacteriaceae, performed between November 2014 140 and November 2016. In this cross-sectional study, every month a random sample of ~2,000 141 residents of the Netherlands was drawn from Dutch municipalities (covering the entire 142 population of the Netherlands). One person per household was invited to fill in a web-based 143 questionnaire, and upon completion of the questionnaire, the participant was asked to provide a 144 faecal sample. ESBL-producing Escherichia coli, Klebsiella pneumoniae, and the Enterobacter 145 cloacae complex were isolated using MacConkey agar with 1 mg/L cefotaxime or after 146 enrichment 2 mL of LB with 1 mg/mL cefotaxime. Up to five colonies with different morphologies 147 were selected. Species identification was performed using MALDITOF-MS (Bruker, Bremen, 148 Germany). ESBL-encoding genes were identified by PCR and isolates negative in the PCR 149
were tested for the presence of other ESBL encoding genes by the Check MDR CT-101 150 microarray (Check-points, Wageningen, the Netherlands). The genes were identified by 151 conventional sequencing. PCR-based Replicon Typing (PBRT) was performed to identify the 152 plasmid type that encoded the ESBL 20 . All ESBL-producing Enterobacteriaceae were stored at 153 -80°C in the UMCU and were subjected to WGS (see Genotyping). Further details of the study 154 design can be found elsewhere 21 . For the current study, only genetic data of the first sampled 155 faecal ESBL-PEc isolate of a patient were collected. No age restrictions were used. 156 that are used in this study. 160
GP, general practitioner; UTI, urinary tract infection 161
Epidemiological variables 162
The following information was collected from all patients: age, sex, postal code, type of infection 163 (community UTI, nosocomial UTI, BSI), date of sample collection, and community or nosocomial 164 (i.e. sample taken >2 days after hospital admission) onset of infection. In addition, for UTIs it 165 was recorded whether the urine sample was a catheter sample. For patients with E. coli BSI, 166 additional information regarding presence of a urinary catheter, hospital ward (ICU versus non-167 ICU), 30-day and 1-year mortality and the primary focus of BSI was obtained from electronic 168 medical records. Possible primary foci were: urinary tract (i.e. pyelonephritis, prostatitis), gastro-169 intestinal (i.e. diverticulitis, bacterial translocation), hepatic-biliary (i.e. cholangitis), respiratory, 170 gynaecological, other (i.e. meningitis, venous catheter), and unknown. The primary focus of BSI 171 (portal of entry) was defined on the basis of clinical and/or radiologic features and the isolation 172 of E. coli from the presumed source of infection. If E. coli was not isolated from the presumed 173 primary focus (i.e. because of previous antimicrobial treatment or invasive procedure that was 174 needed to isolate E. coli from primary source), the presumed primary focus was based on a firm 175 clinical suspicion (given that all other possible sources of infection were excluded). In case of 176 multiple possible primary foci, consensus was reached by discussion by DH and TV. 177
Genotyping
178
All E. coli isolates that were selected for the current study were inoculated on (non-selective) 179 blood agar and species confirmation was performed by MALDITOF-MS prior to WGS, which 180 was performed at the RIVM. All E. coli strains, except the strains from the external dataset, were 181 subjected to WGS using the Illumina HiSeq 2500 (BaseClear, Leiden, the Netherlands). 
Planned analyses 202
Primary objective 1 203
The population structure of ESBL-PEc from the clinical and faecal samples will be compared on 204 three levels. Firstly, the core genome will be assessed with MLST, a core genome phylogeny 205 based on SNP and allelic profile variation using SeqSphere, and the ESBL-PEc populations will 206 be partitioned in sequence clusters. For this, different methods are available like hierarchical 207
Bayesian Analysis of Population Structure (BAPS) or PopPUNK 23,24 . Secondly, the accessory 208 genome will be assessed by comparing acquired resistance genes in the ESBL-PEc populations 209 using Resfinder, and the plasmid composition will be predicted using the recently developed 210 mlplasmid© algorithm 25 . Lastly, a pan-genome analysis will be performed using PANINI, to 211 assess if the total gene content differs per different ESBL-PEc population 26 . 212
Primary objective 2 213
To assess the association between epidemiological characteristics and molecular 214 characteristics of E. coli blood isolates, MLST, virulence and antimicrobial resistance gene 215 content will be described according to the different epidemiological subgroups. A core-genome 216 tree will be constructed with the same method as mentioned above. A virulence score will be 217 made per isolate and will be defined as the total number of virulence genes present in that 218 strain. These virulence scores will then be compared between isolates with different 219 epidemiological characteristics and between ST131 and non-ST131 isolates, respectively. 220
Serotype distribution of the bacteraemia population will be compared to current E. coli vaccine 221
candidates. Furthermore, a genome-wide association approach will be used to see whether any 222 epidemiological characteristics are associated with certain molecular traits. informed consent for the use of clinical data and faecal samples in future studies such as the 231 current study. In this study, in case of age <13 years, parents provided informed consent. In 232 case of age 13-17 years, both the child and parents provided informed consent. 233
DISCUSSION
234
The EPIGENEC study aims to assess the genomic population structure of ESBL-PEc strains 235 from community and nosocomial infections and ESBL-PEc strains representing community 236 faecal carriage. It will also carefully describe the clinical epidemiology and genomic population 237 structure of E. coli BSI, which is important in determining the targets and impact of possible new 238 preventive measures. 239
Strengths 240
One of the key aspects of the current study is the combined use of epidemiological data and 241 detailed whole genome sequence data of strains from several different domains in order to 242 obtain a more complete picture of the current molecular epidemiology of (ESBL-producing) E. 243 coli in the Netherlands. Furthermore, the use of WGS techniques allows us to map the 244 population structure of E. coli and the association of the genomic make-up of strains with their 245 isolation source with high resolution and discriminatory power. Also, all strains were uniformly 246 assembled and analysed, reducing the risk of information bias. 247
Limitations 248
This study also has limitations. Guidelines for Dutch primary care physicians recommend to only 249 send in urine cultures for microbiological testing for patients with complicated UTI (i.e. 250 symptoms accompanied with fever, or in case of male patients with UTI symptoms), clinical 251 treatment failure, recurrent UTIs, or a possibly resistant infection, which implies selection of 252 patients with community UTI. However for our study, we do not consider this to cause selection 253 bias, since we are particularly interested in the molecular epidemiology of ESBL-PEc from urine 254 samples in the way they are currently being performed, so as according to clinical practice. 255
Also, ideally we would be able to pick up time-trends in the change in molecular epidemiology of 256 community faecal carriage of ESBL-PEc and assess whether these trends are reflected in the 257 molecular epidemiology of clinical cultures, for example from community or nosocomial UTI. 258
One could imagine using such results to assess the possible value of ESBL-PEc isolates from 259 clinical cultures as a proxy of changes in the molecular epidemiology of community faecal 260 carriage. However, considering the heterogeneity in the E. coli species and the limited amount 261 of years of which we have faecal samples, this will prohibit us to draw hard conclusions. We still 262 believe this comparison will provide us valuable information and will guide future research on 263 
